alzheimer's disease FDA approvals, PDUFA dates and pipeline.
Updated Snapshot 20261116T222116ZBuilt
We track 8 alzheimer's disease drugs. No FDA approvals recorded yet.
Drugs
| Drug | Sponsor | Modality | Designations |
|---|---|---|---|
| ACI-24 | ACIU | — | Fast Track |
| GSK4527226 | GSK | — | — |
| karxt (BMS-986510) | BMY | — | — |
| NBI-1117567 | NBIX | — | — |
| PMN310 | PMN | — | Fast Track |
| remternetug (LY3372993) | LLY | — | — |
| VHB937 | NVS | — | — |
| xanomeline/trospium chloride (BMS-986510) | BMY | — | — |
Upcoming catalysts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| May 2028Month disclosed | NBI-1117567 | NBIX | Primary completion | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| May to Aug 2028Quarter disclosed | NBI-1117567 | NBIX | Topline readout | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | karxt (BMS-986510) | BMY | Topline readout | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | karxt (BMS-986510) | BMY | Topline readout | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | GSK4527226 | GSK | Topline readout | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | VHB937 | NVS | Topline readout | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | karxt (BMS-986510) | BMY | Primary completion | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | VHB937 | NVS | Primary completion | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | GSK4527226 | GSK | Primary completion | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | xanomeline/trospium chloride (BMS-986510) | BMY | Topline readout | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | xanomeline/trospium chloride (BMS-986510) | BMY | Primary completion | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| April 2029Month disclosed | remternetug (LY3372993) | LLY | Primary completion | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2029Quarter disclosed | remternetug (LY3372993) | LLY | Topline readout | Alzheimer's Disease | Scheduled | ClinicalTrials.gov |
Past catalysts and decisions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| May 14, 2026 | GSK4527226 | GSK | Primary completion | Alzheimer's Disease | Withdrawn | ClinicalTrials.gov |
| late 2024Half-year disclosed | PMN310 | PMN | Trial start | Alzheimer's disease | Scheduled | SEC 8-K Exhibit 99.1 |
All indications · Approval rates by indication
Questions
What alzheimer's disease drugs have upcoming PDUFA dates?
None disclosed.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.